BLLN · Earnings event · Q2 2026 · archived
BillionToOne (BLLN) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.36 vs estimate $0.16 (+124.3%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.16 | $0.36 | +124.3% |
| Revenue (2026-06-30) | — | $109.4M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated BLLN Buy (Wait) at 5.6/10. After the Q2 2026 report, the verdict moved to Hold at 5.5/10.
Healthcare context
BLLN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $4.40B
- P/E (fwd)
- 70.2
- P/E (ttm)
- 129.6
- 52-week range
- $61.96–$150.44
- Off 52-week high
- 37.4%
- RSI (14)
- 33
- Volume vs avg
- 0.58×
- Engine score
- 5.7/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.